Yea Christopher's Form 4 filing
KalVista Pharmaceuticals, Inc. (KALV) · filed May 27, 2026
- Accession no.
- 0001691102-26-000006
- Filed
- May 27, 2026
- Trade date
- May 22-26, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $52.6K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yea ChristopherCIK 0001691102 | Officer (CHIEF DEVELOPMENT OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Common Stock | MOption exerciseAcquired | +3,125 | –F1 | – | 231,884 | Direct | |
| May 26, 2026 | Common Stock | SSaleDisposed | −1,966 | $26.78 | −$52,649.48 | 229,918 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Common Stock | MOption exerciseDisposed | −3,125 | $0.00 | $0 | 25,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Referenced by the price of 1 transaction in Table I.